Our top pick for
The Joint Corp is a medical care facilities business based in the US. The Joint shares (JYNT) are listed on the NASDAQ and all prices are listed in US Dollars. The Joint employs 225 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$82.41|
|52-week range||$17.80 - $111.06|
|50-day moving average||$97.67|
|200-day moving average||$78.10|
|Wall St. target price||$124.60|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.17|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||3.53%|
|1 month (2021-09-24)||-19.21%|
|3 months (2021-07-23)||-0.41%|
|6 months (2021-04-23)||51.43%|
|1 year (2020-10-23)||332.14%|
|2 years (2019-10-23)||310.20%|
|3 years (2018-10-23)||963.03%|
|5 years (2016-10-21)||2,885.87%|
Valuing The Joint stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of The Joint's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
The Joint's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 68x. In other words, The Joint shares trade at around 68x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
The Joint's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $12.5 million.
The EBITDA is a measure of a The Joint's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$70.2 million|
|Operating margin TTM||12.12%|
|Gross profit TTM||$52.2 million|
|Return on assets TTM||8.33%|
|Return on equity TTM||100.13%|
|Market capitalisation||$1.1 billion|
TTM: trailing 12 months
There are currently 1.1 million The Joint shares held short by investors – that's known as The Joint's "short interest". This figure is 28.5% up from 841,984 last month.
There are a few different ways that this level of interest in shorting The Joint shares can be evaluated.
The Joint's "short interest ratio" (SIR) is the quantity of The Joint shares currently shorted divided by the average quantity of The Joint shares traded daily (recently around 162974.24698795). The Joint's SIR currently stands at 6.64. In other words for every 100,000 The Joint shares traded daily on the market, roughly 6640 shares are currently held short.
However The Joint's short interest can also be evaluated against the total number of The Joint shares, or, against the total number of tradable The Joint shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case The Joint's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 The Joint shares in existence, roughly 80 shares are currently held short) or 0.0773% of the tradable shares (for every 100,000 tradable The Joint shares, roughly 77 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against The Joint.
Find out more about how you can short The Joint stock.
We're not expecting The Joint to pay a dividend over the next 12 months.
Over the last 12 months, The Joint's shares have ranged in value from as little as $17.8 up to $111.055. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while The Joint's is 1.2979. This would suggest that The Joint's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of May 11, 2021, the company operated approximately 600 locations in 35 states. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.
Steps to owning and managing Valkyrie Bitcoin Strategy ETF units.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Oct. 21, 2021
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.